Table 3

Description of serious adverse events (SAEs)

CTTTICIOverall
n=293
SARS-CoV-2 negative
n=37
SARS-CoV-2 positive
n=13
SARS-CoV-2 negative n=60SARS-CoV-2 positive
n=24
SARS-CoV-2 negative
n=107
SARS-CoV-2 positive n=52
Hospitalizations:
Yes01 (7.7)2 (1.9)7 (13.5)10 (3.4)
Number of deaths1 (100.0)0 (0.0)4 (57.1)5 (50.0)
Reasons for hospitalization:
Patients with radiographic changes, n (%)0 (0.0)0 (0.0)7 (100.0)7 (70.0)
Patients requiring oxygen, n (%)1 (100.0)0 (0.0)5 (71.4)6 (60.0)
Patients requiring renal replacement therapy, n (%)0 (0.0)0 (0.0)1 (14.3)1 (10.0)
Patients requiring antibiotics therapy, n (%)1 (100.0)0 (0.0)6 (85.7)7 (70.0)
Patients requiring antivirals therapy, n (%)0 (0.0)0 (0.0)3 (50.0)3 (33.3)
 Missing0011
Patients requiring glucocorticoids therapy, n (%)0 (0.0)0 (0.0)2 (33.3)2 (22.2)
 Missing0011
Patients requiring anti-IL6 therapy, n (%)0 (0.0)0 (0.0)2 (33.3)2 (22.2)
 Missing0011
Number of deaths, n (%)1 (2.6)2 (15.4)2 (1.9)6 (11.5)11 (3.8)
  • SARS-CoV-2 positive: one positive result from serologic test confirmed by nasal swab.

  • CT, chemotherapy; ICI, immune checkpoint inhibitors; TT, targeted therapy.